Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONO-5129
- Development stage
- Phase 2
- Lead developer
- Ono Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ONO-5129 is a small molecule drug developed by Ono Pharmaceutical. It acts as a dual agonist of peroxisome proliferator-activated receptor alpha (PPARα) and peroxisome proliferator-activated receptor gamma (PPARγ). These nuclear receptors play key roles in regulating lipid metabolism, glucose homeostasis, and insulin sensitivity. Dual PPARα/γ agonists have been investigated for the treatment of metabolic diseases such as type 2 diabetes mellitus. Clinical trials with ONO-5129 have focused on evaluating its efficacy, safety, and pharmacokinetics in patients with type 2 diabetes mellitus[1][2][3][4].
- Other names
- ONO 5129ONO5129ONO-5129
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on ONO-5129.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONO-5129.